Comparative Pharmacology
Head-to-head clinical analysis: X TROZINE L A versus XYZAL ALLERGY 24HR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: X TROZINE L A versus XYZAL ALLERGY 24HR.
X-TROZINE L.A. vs XYZAL ALLERGY 24HR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
X-TROZINE L.A. is a piperazine derivative that acts as a centrally acting alpha-2 adrenergic agonist, reducing sympathetic outflow from the brainstem, leading to decreased peripheral vascular resistance and lowered blood pressure.
Levocetirizine is the active R-enantiomer of cetirizine, a second-generation antihistamine. It selectively inhibits peripheral H1 receptors, reducing histamine-mediated allergic responses such as itching, sneezing, and rhinorrhea.
250 mg orally once daily. May be increased to 500 mg once daily if needed.
5 mg (1 tablet) orally once daily, preferably in the evening.
None Documented
None Documented
12-15 hours; prolonged in renal impairment (up to 30 hours in CrCl <30 mL/min).
Terminal elimination half-life is approximately 8-9 hours in healthy adults. In patients with renal impairment (CrCl <30 mL/min), half-life may be prolonged to up to 21 hours.
Primarily renal (70-80% as unchanged drug), with 20-30% fecal via biliary excretion.
Primarily renal excretion; approximately 85% of the dose is excreted unchanged in urine, with the remainder as metabolites (mainly the conjugate) in feces via biliary elimination (~10-13%).
Category C
Category C
Antihistamine
Antihistamine